Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Alzinova’s announcements of the operational start-up of the global Phase II study for ALZ-101 and a SEK51m rights issue, securing funding to advance the program.</li><li>We view the progress as being operational positive, but also acknowledge the capital requirements and financing risk related to proceeding with the study independently.</li><li>We believe that this makes the upcoming Phase II program an increasingly important value inflection point.</li></ul>

Redeye comments on Alzinova’s announcements of the operational start-up of the global Phase II study for ALZ-101 and a SEK51m rights issue, securing funding to advance the program.We view the progress as being operational positive, but also acknowledge the capital requirements and financing risk related to proceeding with the study independently.We believe that this makes the upcoming Phase II program an increasingly important value inflection point.

Alzinova: Phase II study update and SEK51 rights issue